drugset / Trial / NCT06610266

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

NCT06610266

Phase 4 Recruiting 400 enrolled Yongquan Shi
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.

Timeline

Start
2025-02-28
Primary completion
2026-10-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Weifuchun Traditional medicine (herbal / TCM) 1400 mg Oral
Comparator folic acid Other / unclassified 5 mg Oral